Nilestriol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nilestriol
Nilestriol.svg
Identifiers
Systematic (IUPAC) name: (1S,10R,11S,13R,14R,15S)-5-(cyclopentyloxy)-14-ethynyl-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-13,14-diol
CAS Number 39791-20-3
PubChem (CID) 38346
ChemSpider 35146
UNII 7JA3B3IALU
KEGG D05212
ChEMBL CHEMBL2104468
Chemical and physical data
Formula C25H32O3
Molar mass 380.51978 g/mol
3D model (Jmol) Interactive image

Nilestriol (INN) (brand name Wei Ni An; developmental code name LY-49825), also known as nylestriol (USAN, BAN), is a synthetic, steroidal estrogen that was patented in 1971[1] and is marketed in China.[2][3] It is the 3-cyclopentyl ether of ethinyl estriol, and is also known as ethinyl estriol cyclopentyl ether (EE3CPE).[4] Nilestriol is a prodrug of ethinyl estriol, and is a more potent estrogen in comparison.[4] It is described as a slowly-metabolized, long-acting estrogen and derivative of estriol.[5][6] Nilestriol was assessed in combination with levonorgestrel for the potential treatment of postmenopausal osteoporosis, but this formulation ultimately was not marketed.[7]

See also[edit]

References[edit]

  1. ^ Official Gazette of the United States Patent and Trademark Office: Patents. U.S. Department of Commerce, Patent and Trademark Office. 1975. p. 1677. 
  2. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 891–. ISBN 978-1-4757-2085-3. 
  3. ^ https://www.drugs.com/international/nilestriol.html
  4. ^ a b William McGuire (14 December 2013). Experimental Biology. Springer Science & Business Media. pp. 161–. ISBN 978-1-4757-4673-0. 
  5. ^ Daniel Robert Schoenberg (1977). Biochemical Properties of the Cytoplasmic Estrogen Receptors from Immature Rat and Mature Rabbit Uteri. University of Wisconsin. p. A-17. 
  6. ^ Excerpta medica. Section 10: Obstetrics and gynecology. 1978. 
  7. ^ Jeffrey K. Aronson (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 173–. ISBN 978-0-08-093292-7.